Nick joined Elusys Therapeutics in December 2024 with an extensive background in Pharmaceutical and Biotech finance.  He maintains a CPA license in North Carolina, and comes with a successful track record of transforming small Finance teams through lean process improvements, short- and long-term strategic planning, and systems planning and administration.  Most recently, he was instrumental in the US commercial launch of BAFIERTAM® at Banner Life Sciences in September 2020.  Prior to this, Nick was a key contributor to the US financial and commercial operations for the TUDORZA®, DUAKLIR®, and NIOX® brands at NIOX Group plc (formerly Circassia Pharmaceuticals) since 2008.